SCHEDULE 13G/A: Tang Capital Affiliates Maintain 7.0% Stake in CytomX
Beneficial Ownership Report
Tang Capital Management and its affiliates report a 7.0% beneficial ownership stake in CytomX Therapeutics, Inc. through a Schedule 13G/A filing.
Summary
- Tang Capital Management, LLC, Kevin Tang, Tang Capital Partners, LP, and Tang Capital Partners International, LP collectively beneficially own 11,065,662 shares of CytomX Therapeutics, Inc. common stock.
- This ownership represents 7.0% of the company's total outstanding common stock.
- The percentage is calculated based on 157,544,369 shares of Common Stock outstanding as of May 9, 2025.
- The reporting persons share both voting and dispositive power over these 11,065,662 shares.
- This filing is an Amendment No. 5 to a previously filed Schedule 13G.
Sentiment
Score: 6
Explanation: A Schedule 13G filing is primarily an informational disclosure of ownership. The continued significant stake by an institutional investor like Tang Capital can be viewed as a neutral to slightly positive signal of ongoing confidence, but it does not provide operational or financial performance details to significantly alter sentiment.
Positives
- Tang Capital Management and its affiliates continue to hold a significant 7.0% beneficial ownership stake in CytomX Therapeutics, indicating sustained investment interest from a notable institutional investor.
Future Outlook
The filing does not provide any forward-looking statements or guidance regarding CytomX Therapeutics' future performance or strategic direction.
Management Comments
- The securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.
Industry Context
This filing is a routine disclosure of beneficial ownership by an institutional investor in a biotechnology company. It reflects investment activity within the sector rather than specific industry trends or competitive developments.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's investment, which may influence broader investor sentiment.
Key Dates
| Date | Description |
|---|---|
| 2025-05-09 | Date on which 157,544,369 shares of Common Stock were reported as outstanding. |
| 2025-05-12 | Date Prospectus Report on Form 424B5 was filed with the SEC. |
| 2025-06-30 | Date of the event which required the filing of this statement. |
| 2025-08-14 | Signature date of the Schedule 13G/A filing. |
Keywords
CytomX Therapeutics, CMTX, Tang Capital Management, Kevin Tang, Beneficial Ownership, Schedule 13G, Biotechnology, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.